Shire announced that CFO Jeff Poulton will be leaving the company at the end of the year. Additionally, Joanne Cordeiro has been appointed as CHRO.
On August 21, 2017, Shire, a biotechnology company focused on developing therapies for rare diseases, announced that chief financial officer (CFO) Jeff Poulton will be leaving the company at the end of the year to serve as CFO at Indigo, a start-up company based in Boston that uses the plant microbiome to improve the productivity and sustainability of agriculture. Poulton will continue to serve as CFO as the board conducts a formal search for his successor. During this transition period, Poulton will also remain on the company’s executive committee and board of directors, and will continue to support the company’s on-going business review.
“It has been a privilege to work for Shire and to have played a part in the exceptional growth story of such an inspirational company. It has been a difficult decision, but in departing Shire, I wanted to join a smaller organization where I can play a role in building a new company,” said Poulton, in a company press release. “As Shire finalizes the integration of Baxalta and focuses on paying down debt, this also presents a perfect time for me to begin this transition. I know I leave Shire well positioned to pursue its strategy and deliver value for shareholders, supported by a strong Finance team.”
Effective immediately, the company also announced Joanne Cordeiro as their new chief human resources officer and member of the executive committee. She takes over the role previously held by Ginger Gregory. Cordeiro joined Shire in March 2011 and has been serving as interim head of human resources since March 2017.
Source: Shire
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.